-Live Mint     Gujarat has grown faster than the national average—a point worth noting. But there’s no need for drumbeats  Gujarat's economic performance has been facing great scrutiny ever since chief minister Narendra Modi emerged as one of the top prime ministerial candidates of the Bharatiya Janata Party (BJP). I have been asked to compare Gujarat's economic performance during the past decade with that in the past and separate fact from fiction...

-The Economic Times NEW DELHI: Narendra Modi's Gujarat government, lauded by India Inc for being business friendly, has stumped industry as it seeks to back out of the high tariffs contracted for nearly 1,000 MW of solar plants of the Tatas, GMR, Adani, Bollywood star Ajay Devgn, Lanco and others. Industry leaders said the move was shocking as it raised issues about the consistency of the state's policy, but the business-savvy Gujarat...

-The Economic Times CHENNAI: India's patent appeals board has denied Monsanto a patent for a genetically-engineered method of increasing climate resilience in plants. The decision is significant not only for Monsanto's loss of possible exclusivity in an increasingly important segment but also for the interpretation of India's home-grown clauses in patent law - these are unpopular with global companies - for the first time in the case of plants. The Intellectual Property...

-Reuters India has launched a wide-ranging surveillance programme that will give its security agencies and even income tax officials the ability to tap directly into e-mails and phone calls without oversight by courts or parliament, several sources said. The expanded surveillance in the world's most populous democracy, which the government says will help safeguard national security, has alarmed privacy advocates at a time when allegations of massive US digital snooping beyond American...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...